Minhai was invited to attend the 18th Annual Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN), held in Seoul, South Korea.

Release date:

2017-11-27

Author:

International Cooperation Department, Xie Luoyunpiao

Source:


Abstract

Recently, Minhai, as one of the member companies of the Developing Countries Vaccine Manufacturers Network (DCVMN), was invited to attend the 18th Annual Meeting of the DCVMN, held in Seoul, South Korea. The conference brought together representatives from the World Health Organization (WHO), UNICEF, the Global Alliance for Vaccines and Immunization (GAVI), the Bill & Melinda Gates Foundation, as well as more than 50 member companies.

  Recently, Minhai, as one of the member companies of the Developing Countries Vaccine Manufacturers Network (DCVMN), was invited to attend the 18th Annual Meeting of the DCVMN, held in Seoul, South Korea.

  The meeting was attended by representatives from the World Health Organization (WHO), the United Nations Children’s Fund (UNICEF), the Global Alliance for Vaccines and Immunization (GAVI), the Bill & Melinda Gates Foundation, as well as more than 50 member companies of the alliance.

  The main topics discussed during the conference included accelerating vaccine development for epidemic prevention, conceptualizing partnerships to strengthen the vaccine industry in developing countries, conducting joint reviews to enhance regulatory capacity in these countries, and promoting vaccine registration in developing nations as well as the research and development of new vaccines.

  Through this conference, Minhai gained a deeper understanding of global emerging vaccine technologies and market trends, new international regulatory‑harmonization trends and requirements, and the progress of sIPV manufacturing projects worldwide. At the same time, the company engaged in exchanges and discussions with numerous international organizations and firms regarding its current product portfolio, new projects, and innovative products, thereby providing valuable and actionable insights to support the future WHO prequalification of Minhai’s vaccine offerings, ensure compliance with international quality standards, and advance the company’s global expansion.

 

Recommended Reading


Batch Release Status of the Company’s Products in 2026


The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.


Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.


Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09